Indications & Dose: CONTRACEPTION Combination therapy PO Adult 20-40µg with other oral contraceptives | FEMALE HYPOGONADISM PO Adult 10-50µg/day | MALIGNANT NEOPLASMS OF BREAST PO Adult 100µg-1mg TID in postmenopausal women | MENOPAUSAL HORMONE REPLACEMENT THERAPY Combination therapy PO Adult 10-50µg/day given with progestogen in women with intact uterus | PROSTATE CANCER Palliative therapy PO Adult 150µg-3mg/day

Precautions: Antiphospholipid antibodies/predisposing factors to thromboembolism, migraine, history of breast nodules/fibrocystic disease, uterine fibroids, history of endometriosis, history of cholestatic jaundice, asthma

ADR: Serious: Endometrial carcinoma, palliation of cancers, cholestatic jaundice, withdrawal bleeding, hypercalcemia, gynecomastia, venous & arterial thrombosis, breast cancer, impotence, hypersensitivity reactions, Others: Nausea, vomiting, abdominal cramps, weight changes, dizziness, changes in libido, migraine, breast enlargement & tenderness, depression, mood changes, headache, leg cramps, vaginal candidiasis, decreased tolerance of contact lenses, local irritation, rhinorrhea, epistaxis, fluid retention, glucose intolerance, altered blood lipids, premenstrual-like syndrome, rashes

DDI: Serious Ropinirole clearance increased, Etoricoxib/Cotrimoxazole/Lovastatin/Miconazole increases drug levels, Cyproterone increases risk of contraceptive failure, Minocycline leads to facial pigmentation, Quinolones levels decreased, Clozapine/Chlorpromazine/Propranolol levels increased, Colestipol/Barbiturates/Colestyramine reduces drug absorption, Carbamazepine/Aprepitant/Phenobarbital/Phenytoin/Topiramate reduces drug levels